425 related articles for article (PubMed ID: 33758605)
1. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
[No Abstract] [Full Text] [Related]
2. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.
Xiong Y; Shi LL; Zhu LS; Peng G
Ann Palliat Med; 2021 Apr; 10(4):4122-4133. PubMed ID: 33832314
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio-EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy.
Huang ZZ; Wen W; Hua X; Song CG; Bi XW; Huang JJ; Xia W; Yuan ZY
Front Oncol; 2021; 11():583283. PubMed ID: 34336633
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
6. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
[TBL] [Abstract][Full Text] [Related]
7. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load.
Jiang YT; Chen KH; Yang J; Liang ZG; Qu S; Li L; Zhu XD
Front Oncol; 2021; 11():683475. PubMed ID: 34222003
[TBL] [Abstract][Full Text] [Related]
9. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
10. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index during treatment predicts prognosis and guides clinical treatment in patients with nasopharyngeal carcinoma.
Yuan X; Feng H; Huang H; Li J; Wu S; Yuan Y; Cui L; Lin D; Chen Z; Lu W; Liu X; Peng X; Wang F
J Cancer Res Clin Oncol; 2023 Jan; 149(1):191-202. PubMed ID: 36595043
[TBL] [Abstract][Full Text] [Related]
12. Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.
Hua X; Li WZ; Huang X; Wen W; Huang HY; Long ZQ; Lin HX; Yuan ZY; Guo L
Front Oncol; 2021; 11():625534. PubMed ID: 33777769
[TBL] [Abstract][Full Text] [Related]
13. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
14. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study.
Lu H; Guo S; Liu L; Chen Q; Liang Y; Liu S; Sun X; Tang Q; Li X; Guo L; Mo H; Tang L; Mai H
Cancer Biol Med; 2021 Jun; 19(4):551-64. PubMed ID: 34132505
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study.
Oei RW; Ye L; Kong F; Du C; Zhai R; Xu T; Shen C; Wang X; He X; Kong L; Hu C; Ying H
Cancer Manag Res; 2018; 10():2785-2797. PubMed ID: 30147375
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients.
Zhang N; Hou T; Zhang S; Ling J; Jiang S; Xie Y; Liu X; Hu C; Feng Y
Heliyon; 2024 Jan; 10(2):e24804. PubMed ID: 38312571
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
20. Significance of Pre-Treatment CALLY Score Combined with EBV-DNA Levels for Prognostication in Non-Metastatic Nasopharyngeal Cancer Patients: A Clinical Perspective.
Jiang T; Sun H; Xu T; Xue S; Xia W; Xiao X; Wang Y; Guo L; Lin H
J Inflamm Res; 2024; 17():3353-3369. PubMed ID: 38803689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
